Biosight Ltd., of Airport City, Israel, reported final results in a phase I/II multicenter, open-label, dose-escalating study of its lead product, BST-236, a cytarabine prodrug, as a single agent for induction therapy in acute leukemia patients. The results, presented at the 59th Annual American Society of Hematology Meeting in Atlanta, demonstrated safety and efficacy of BST-236 as a single agent in treatment of newly diagnosed acute leukemia patients unfit for standard induction therapy, the company said. Read More
Pain Therapeutics Inc., of Austin, Texas, said an altered form of a protein called filamin A (FLNA) that is critical to the formation of neuropathologies associated with Alzheimer’s disease is described in Neuroimmunology and Neuroinflammation. Read More
Telix Pharmaceuticals Ltd., of Melbourne, Australia, appointed Bernard Lambert president and chief operating officer of its U.S. subsidiary, Telix Pharmaceuticals (US) Inc. Read More
Vistagen Therapeutics Inc., of South San Francisco, closed its public offering of 10 million shares of common stock and warrants to purchase up to 10 million shares at a combined offering price of $1.50 per share and related warrant. Gross proceeds totaled $15 million. Read More
PERTH, Australia – IP Australia released its final recommendations on five separate intellectual property policy amendments put forward by the Productivity Commission that are expected to make their way through Parliament in 2018. Read More
Given the ever-present hype around artificial intelligence (AI) as transformative to entire industries, including health care, it’s always useful to take a close look at the data. One of the latest efforts on that front was an analysis of several competing deep learning algorithms used to detect the spread of breast cancer to the lymph nodes that was recently published in the Journal of the American Medical Association (JAMA). Read More
New pivotal phase III results positioning the nonsteroidal anti-inflammatory Ampion for potential approval in severe osteoarthritis of the knee (OAK) pushed shares of its developer, Ampio Pharmaceuticals Inc. (NYSE:AMPE), to touch a 52-week high on Thursday before pulling back somewhat, closing 33.1 percent higher at $2.33. Read More
Sitting “right in the center” of intensified computing power and new experimental methods lets Relay Therapeutics Inc. pursue its method of “bouncing between the virtual and physical world constantly,” CEO Sanjiv Patel told BioWorld, and could mean a powerful change in how drugs are developed, in cancer and beyond. Read More
DUBLIN – Remynd NV could earn up to €350 million (US$412 million) in up-front, research and milestone payments from a licensing deal with Novo Nordisk A/S focused on its preclinical diabetes drug candidate ReS39. Read More
Trade officials for the EU, Japan and the U.S. issued a joint statement this week agreeing to enhance their cooperation in the World Trade Organization and other forums to create a global level playing field by eliminating “unfair market distorting and protectionist practices by third countries.” Read More
